Rational Pharmacotherapy in Cardiology

Advanced search

The Peculiarity of Process and Treatment of Arterial Hypertension in Patients with Type 2 Diabetes Mellitus

Full Text:


Arterial hypertension (AH) is powerful and modifying factor of developing macrovascular and microvascular complications of diabetes. Patients with AH and diabetes belong to group with high and very high levels risk of developing cardiovascular complications and chronic kidney disease. The combination of type 2 diabetes mellitus and AH dramatically increases the risk of developing terminal stages of microvascular and macrovascular diabetic complications: blindness, end-stage chronic kidney disease, amputation of the lower extremities, myocardial infarction, cerebral stroke, worsens the patients prognosis and quality of life. There is ample evidence that blood pressure control in diabetic patients may be critical for improving long-term prognosis. This observation does not lose its relevance even with the emergence of new antidiabetic drugs with proven cardio- and nephroprotective effects. Modern clinical researchers and meta-analysis show the priority of combined antihypertensive therapy, which increases the efficacy of blood pressure correction and prophylaxis of long-term complications in patients with type 2 diabetes. In this article we want to pay attention to features of AH in patients with diabetes, to bi-directional pathogenic mechanisms, to discuss the new algorithms of the treatment and therapeutic needs of these patients. It is important to accent the understanding of the integrity and unity of pathogenic mechanisms which are needed in correction. Innovative antihyperglycemic therapy demonstrates the ability of blood pressure decrease. The synergy of effects let us successfully realize the strategy of multi-factor control and reduce a risk of micro- and macrovascular complications.

About the Authors

T. Yu. Demidova
Pirogov Russian National Research Medical University
Russian Federation

Tatyana Yu. Demidova – MD, PhD, Professor, Head of Chair of Endocrinology

Ostrovitianova ul. 1, Moscow, 117997

O. A. Kislyak
Pirogov Russian National Research Medical University
Russian Federation

Oksana A. Kislyak – MD, PhD, Professor, Head of Chair of Faculty Therapy

Ostrovitianova ul. 1, Moscow, 117997


1. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-104. DOI:10.1093/eurheartj/ehy339.

2. Cowie C.C. Diabetes Diagnosis and Control: Missed Opportunities to Improve Health : The 2018 Kelly West Award Lecture. Diabetes Care. 2019;42(6):994‐1004. DOI:10.2337/dci18-0047.

3. Nowakowska M., Zghebi S.S., Ashcroft D.M., et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2020 Jan 25;18(1):22]. BMC Med. 2019;17(1):145. DOI:10.1186/s12916-019-1373-y.

4. Stamler J., Vaccaro O., Neaton J.D, Wentworth D., for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-44. DOI:10.2337/diacare.16.2.434.

5. U.K. Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type II diabetes: UKPDS 39. Br Med J. 1998;317:713-20.

6. Hanson L., Zanchetti A., Carruthers S.3G., et al. Effects of intensive blood pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-62. DOI:10.1016/s0140-6736(98)04311-6.

7. Dedov I.I., Shestakova M.V. Diabetes mellitus and arterial hypertension. Moscow: MIA; 2006 [Дедов И.И., Шестакова М.В. Сахарный диабет и артериальная гипертензия. М.: МИА; 2006].

8. Lau Т., Carlsson P.O., Leung P.S. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia. 2004;47:240-8. DOI:10.1007/s00125-003-1295-1.

9. Reyes-Pardo H., Bautista R., Vargas-Robles H., et al. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage. BMC Nephrol. 2019;20(1):292. DOI:10.1186/s12882-019-1490-z.

10. Patel D.M., Bose M., Cooper M.E. Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease. Int J Mol Sci. 2020;21(6):2218. DOI:10.3390/ijms21062218

11. van Bommel E.J., Muskiet M.H., Tonneijck L., et al. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome. Clin J Am Soc Nephrol. 2017;12(4):700‐10. DOI:10.2215/CJN.06080616.

12. Fioretto P., Frascati A. Role of incretin based therapies in the treatment of diabetic kidney disease. Diabetes Mellitus. 2018;21(5):395-398. DOI:10.14341/DM9845.

13. Dedov I.I., Shestakova M.V., Maiorov A.Yu. Algorithms for specialized medical care for patients with diabetes mellitus. 9th edition (supplemented). Moscow: Russian Association of Endocrinologists; 2019 (In Russ.) DOI:10.14341/DM221S1.

14. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):37-86 (In Russ.) DOI:10.15829/1560-4071-2020-3-3786.

15. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. DOI:10.1093/eurheartj/ehz486.

16. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85. DOI:10.1056/NEJMoa1001286.

17. Chazova I.E., Zhernakova Yu.V. on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31 (In Russ.)

18. Roush G.C., Kaur R., Ernst M.E. Diuretics: a review and update. J Cardiovasc Pharmacol Ther. 2014;(1):5-13. DOI:10.1177/1074248413497257.

19. Patel A., ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829-40. DOI:10.1016/S0140-6736(07)61303-8.

20. Grossman A., Grossman E. Blood pressure control in type 2 diabetic patients. Cardiovasc Diabetol. 2017;16(1):3. DOI:10.1186/s12933-016-0485-3.

21. Rahman F., McEvoy J.W., Ohkuma T., et al. Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus. Hypertension. 2019;73(6):1291‐9. DOI:10.1161/HYPERTENSIONAHA.118.12414.

22. Spirk D., Noll S., Burnier M., et al. First Line CombinAtion Therapy in the Treatment of Stage II and III Hypertension (FLASH). Front Cardiovasc Med. 2020;7:46. DOI:10.3389/fcvm.2020.00046.

23. Paz M.A., de-La-Sierra A., Sáez M., et al. Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine (Baltimore). 2016;95(30):e4071. DOI:10.1097/MD.0000000000004071.

24. Kim Y.H., Her A.Y., Rha S.W., et al. Calcium channel blocker monotherapy versus combination with renin-angiotensin system inhibitors on the development of new-onset diabetes mellitus in hypertensive Korean patients. J Geriatr Cardiol. 2019;16(6):439‐47. DOI:10.11909/j.issn.1671-5411.2019.06.003.

25. Pongpanich P., Pitakpaiboonkul P., Takkavatakarn K., et al. The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis. International Urology and Nephrology. 2018 Dec. DOI:10.1007/s11255-018-1991-x.

26. Bakris G.L., Sarafidis P.A., et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375(9721):1173-81. DOI:10.1016/S0140-6736(09)62100-0.

27. Kario K., Tomitani N., Kanegae H., et al. Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring- The NOCTURNE Study. Circ J. 2017;81(7):948‐57. DOI:10.1253/circj.CJ-17-0109.

28. Anichkov D.A., Shostak N.A., Schastnaya O.V. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res Opin. 2005;21(1):113-119. DOI:10.1185/030079904x20277.

29. Stergiou G.S., Efstathiou S.P., Roussias L.G., et al. Blood pressure- and pulse pressure-lowering effects, trough: peak ratio and smoothness index of telmisartan compared with lisinopril. J Cardiovasc Pharmacol. 2003;42(4):491-6. DOI:10.1097/00005344-200310000-00006.

30. Mancia G., Zanchetti A., Agabiti-Rosei E., et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation. 1997;95(6):1464-70. DOI:10.1161/01.cir.95.6.1464.

31. Rosei E.A., Rizzoni D., Comini S., et al. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. Blood Press Suppl. 2003;1:30-5. DOI:10.1080/08038020310000104.

32. Jensen H.A. Efficacy and tolerability of lisinopril compared with extended release felodipine in patients with essential hypertension. Danish Cooperative Study Group. Clin Exp Hypertens A. 1992;14(6):1095-110. DOI:10.3109/10641969209038195.

33. Os I., Bratland B., Dahløf B., et al. Lisinopril or nifedipine in essential hypertension? A Norwegian multicenter study on efficacy, tolerability and quality of life in 828 patients. J Hypertens. 1991;9(12):1097-104.

34. Instructions for medical use of the drug Diroton LP-004534 from 13.11.2017 [cited by Jul 20, 2020]. Available from: (In Russ.)

35. Lin J.J., Chang H.C., Ku C.T., Chen H.Y. Hydrochlorothiazide hypertension treatment induced metabolic effects in type 2 diabetes: a meta-analysis of parallel-design RCTs. Eur Rev Med Pharmacol Sci. 2016;20(13):2926‐34.

36. Roush G.C., Abdelfattah R., Song S., et al. Hydrochlorothiazide and alternative diuretics versus reninangiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head metaanalysis. J Hypertens. 2018 ;36(6):1247-55. DOI:10.1097/HJH.0000000000001691.

37. Lv X., Zhang Y., Niu Y., Song Q., Zhao Q. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2018;97(15):e0256. DOI:10.1097/MD.00000000000102561.

38. Mamedov M.N., Halimov Yu.S., Agafonov P.V., et al. A new revision of the recommendations of the American Diabetes Association for arterial hypertension in patients with diabetes mellitus: comments by Russian experts 2017. International Journal of Heart and Vascular Diseases. 2017;5(16):3-15 (In Russ.)

39. Bangalore S., Kumar S., Lobach I., Messerli F.H. Blood pressure targets in subjects with type 2 diabetes mellitus/ impaired fasting glucose: observations from traditional and Bayesian random-effects metaanalyses of randomized trials. Circulation. 2011;123:2799-810. DOI:10.1161/CIRCULATIONAHA.110.016337.

40. Kaplan N.M. Indapamide: is it the better diuretic for hypertension? Hypertension. 2015;65(5):983- 4. DOI:10.1161/HYPERTENSIONAHA.115.05138.

41. Olde Engberink R.H., Frenkel W.J., van den Bogaard B., et al. Effects of thiazide-type and thiazidelike diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension. 2015; 65(5):1033-40. DOI:10.1161/HYPERTENSIONAHA.114.05122.

42. Liang W., Ma H., Cao L., et al. Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis. J Cell Mol Med. 2017; 21(11):2634-42. DOI:10.1111/jcmm.13205.

43. Webster R., Salam A., de Silva H.A., et al. Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial. JAMA. 2018;320(6):566‐79. DOI:10.1001/jama.2018.10359.

44. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922-44. DOI:10.1097/HJH.0000000000001276.

For citation:

Demidova T.Yu., Kislyak O.A. The Peculiarity of Process and Treatment of Arterial Hypertension in Patients with Type 2 Diabetes Mellitus. Rational Pharmacotherapy in Cardiology. 2020;16(4):623-634. (In Russ.)

Views: 55

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)